Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Cancer Lett. 2022 Jun 10;543:215779. doi: 10.1016/j.canlet.2022.215779

Figure 6: Versican increases invasion and adhesion to the ovary in an EGFR-dependent manner.

Figure 6:

Boyden chamber invasion assay of (A-B) MOE cells and FT33-TAg cells (C-D) incubated with versican 100 ng/ml for 24h −/+ EGFR inhibitor (EGFRi) 1 μM. Adhesion to the ovary of fluorescently labeled MOE cells (E and G) FT33-TAg cells (F and H) after treatment with versican 100 ng/ml for 24h −/+ EGFR inhibitor 1 μM. A minimum of three independent experiments, biological replicates were analyzed using one-way ANOVA (ns>0.05, p*<0.05, p**<0.01, p***<0.001, P****<0.0001).